Analysts Set Smith & Nephew plc (LON:SN) Price Target at GBX 1,381.33

Shares of Smith & Nephew plc (LON:SN) have earned a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is GBX 1,381.33.

Several research firms have recently commented on SN. Berenberg Bank reissued a “hold” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a research report on Friday, January 23rd. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,350 price objective on shares of Smith & Nephew in a research report on Tuesday, March 17th.

Smith & Nephew Stock Down 0.4%

Smith & Nephew stock opened at GBX 1,262.50 on Friday. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The stock has a market capitalization of £13.84 billion, a price-to-earnings ratio of 45.45, a P/E/G ratio of 0.46 and a beta of 0.74. The business’s fifty day moving average is GBX 1,261.58 and its two-hundred day moving average is GBX 1,268.46.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.